Ketone Body-Induced Ferroptosis Inhibition in Stroke Neuroprotection

Study Background and Research Question

Ischemic stroke remains a leading cause of adult mortality and long-term disability worldwide, with increasing incidence, particularly among younger populations. Despite advances in acute reperfusion therapies, effective neuroprotective interventions for mitigating poststroke neuronal death are lacking. Remote ischemic postconditioning (RIPostC) – a process involving transient, non-lethal ischemia applied to limbs or distant organs – has shown promise in reducing tissue damage following ischemic events. However, the underlying cellular and molecular mechanisms, especially those related to energy metabolism, have not been fully clarified.

This study (ACS Chem. Neurosci. 2024, 15, 2223−2232) asks: does RIPostC confer neuroprotection after ischemic stroke by modulating ketone body metabolism, and if so, how does this relate to the regulation of ferroptosis—a recently characterized, iron-dependent form of cell death linked to lipid peroxidation?

Key Innovation from the Reference Study

The central innovation is the identification of a mechanistic link between RIPostC, increased ketone body production, and the suppression of ferroptosis in the context of ischemic stroke. Specifically, the authors demonstrate that ketone bodies—such as 3-hydroxybutyrate (BHBA), a primary fatty acid β-oxidation metabolite—mediate neuroprotection by inhibiting ferroptotic pathways. This adds a new dimension to our understanding of energy metabolism in stroke pathology, connecting metabolic adaptation with the regulation of neuronal cell death.

Methods and Experimental Design Insights

The research utilized a rat middle cerebral artery occlusion (MCAO) model to simulate ischemic stroke, followed by application of RIPostC. This was achieved by subjecting animals to repeated cycles of limb ischemia and reperfusion post-stroke onset. Neurological deficits were quantified using modified neurological severity scores (mNSS), and motor function was evaluated via open field testing. Histological analyses (TTC staining, TUNEL assays) were performed to assess infarct size and neuronal apoptosis.

For mechanistic studies, the team measured ATP and lactate levels to evaluate shifts in cerebral energy metabolism. Ketone body levels were assessed post-RIPostC, and downstream ferroptosis markers were analyzed, including glutathione peroxidase 4 (GPX4), long-chain acyl-CoA synthetase family member 4 (ACSL4), lipid peroxidation, and iron content. Complementary in vitro experiments used HT22 neuronal cells subjected to oxygen-glucose deprivation/reoxygenation (OGD/R), with or without addition of exogenous ketone bodies, to dissect cellular pathways. Ferroptosis was further probed using erastin, a canonical ferroptosis inducer.

Protocol Parameters

• RIPostC timing: Initiated immediately after reperfusion in the MCAO rat model, using several cycles of limb ischemia/reperfusion (specific cycle parameters detailed in the study's supplementary materials).
• Behavioral assessment: mNSS and open field testing performed 24 hours post-stroke to evaluate neurological and motor function.
• Ketone body measurement: Quantified in brain tissue and serum post-RIPostC.
• In vitro OGD/R model: HT22 cells exposed to hypoxia and glucose deprivation, then reoxygenation, supplemented with ketone bodies at physiologically relevant concentrations (low millimolar range, as in previous literature).
• Ferroptosis modulation: Erastin used to induce ferroptosis and test the specificity of ketone body-mediated protection.

Core Findings and Why They Matter

The study's results provide several lines of evidence supporting the neuroprotective role of ketone bodies after ischemic stroke, mediated through ferroptosis inhibition:

• RIPostC reduced infarct size and improved neurological function in the MCAO rat model, as reflected by decreased tissue damage, better behavioral outcomes, and lower rates of neuronal apoptosis (reference study).
• Enhanced energy metabolism: RIPostC increased ATP levels and reduced lactate accumulation, indicating a metabolic shift that supports neuronal survival.
• Upregulation of ketone bodies: RIPostC led to increased cerebral ketone body concentrations, positioning these metabolites as central mediators of the observed neuroprotection.
• Suppression of ferroptosis: Key ferroptosis regulators were modulated: GPX4 (an antioxidant selenoenzyme) levels were preserved, while ACSL4 (which promotes lipid peroxidation) expression was reduced. Lipid peroxidation and iron accumulation were both attenuated by RIPostC and ketone body supplementation.
• Cellular and mitochondrial protection: In vitro, ketone bodies maintained mitochondrial cristae structure and prevented erastin-induced ferroptosis in HT22 cells, reinforcing the in vivo findings.

Together, these results suggest that targeting metabolic pathways—specifically, boosting ketone body signaling molecules—could represent an effective strategy for mitigating ferroptosis and neuronal loss after ischemic brain injury.

Limitations and Transferability

While these findings offer valuable mechanistic insights, several limitations should be considered:

• Species and model specificity: The primary data are from a rat model of focal cerebral ischemia and may not fully recapitulate human stroke heterogeneity.
• Ketone body diversity: Although the study highlights BHBA and related metabolites, the relative contributions of different ketone bodies (e.g., acetoacetate, acetone) remain to be dissected.
• Dosing and timing: The optimal window and concentration for ketone body administration—clinically or experimentally—require further validation.
• Mechanistic breadth: The research focused on ferroptosis; other cell death pathways (e.g., apoptosis, necroptosis) may also contribute to neuroprotection and warrant exploration.

Despite these caveats, the study establishes a strong rationale for further preclinical and translational research on ketone body metabolism and ferroptosis in brain injury models.

Comparison with Existing Internal Articles

At present, there are no directly comparable internal articles detailing the mechanistic intersection of ketone body metabolism, ferroptosis, and neuroprotection in stroke. However, researchers investigating metabolic disease research compounds or epigenetic modulators may find parallels in how small molecule metabolites—such as 3-hydroxybutyrate—can influence cellular fate via signaling and transcriptional regulation. As more studies emerge, mapping these cross-domain effects will become increasingly relevant for drug discovery pipelines targeting metabolic and chromatin-associated pathways.

Research Support Resources

Researchers aiming to model ketone body signaling or study the effects of fatty acid β-oxidation metabolites in vitro or in vivo can utilize 3-hydroxybutyrate (BHBA) (SKU M1297) from APExBIO. This compound is widely used for mimicking physiological or pathophysiological ketosis, supporting investigations into energy metabolism, ferroptosis, and histone deacetylase inhibition in cell-based or animal models. For dosing guidance and handling, consult the product information. Proper storage and solution preparation are recommended to maintain compound integrity for experimental reproducibility.